BTK and B-cell chronic lymphocytic leukemia: In contrast to ibrutinib, MT-802 was able to reduce the pool of active BTK in primary cells isolated from chronic lymphocytic leukemia (CLL) patients bearing C481S mutation (Buhimschi et al., 2018).